Daniel D Murray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1677842/publications.pdf

Version: 2024-02-01

22 papers 986 citations 686830 13 h-index 752256 20 g-index

26 all docs 26 docs citations

times ranked

26

2317 citing authors

#	Article	IF	Citations
1	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). Clinical Trials, 2022, 19, 52-61.	0.7	16
2	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, The, 2022, 399, 530-540.	6.3	48
3	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. Annals of Internal Medicine, 2022, 175, 234-243.	2.0	56
4	Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 72, 1141-1146.	2.9	2
5	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 905-914.	13.9	357
6	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. Journal of Infectious Diseases, 2021, 224, 2053-2063.	1.9	6
7	The central role of the glutamate metabolism in long-term antiretroviral treated HIV-infected individuals with metabolic syndrome. Aging, 2021, 13, 22732-22751.	1.4	14
8	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. Aids, 2021, 35, 783-789.	1.0	2
9	Integrative Lipidomics and Metabolomics for System-Level Understanding of the Metabolic Syndrome in Long-Term Treated HIV-Infected Individuals. Frontiers in Immunology, 2021, 12, 742736.	2.2	11
10	Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. American Journal of Hypertension, 2020, 33, 43-52.	1.0	6
11	Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients. Blood Advances, 2020, 4, 5797-5809.	2.5	42
12	Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance. Journal of Clinical Medicine, 2019, 8, 1163.	1.0	16
13	2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients. Open Forum Infectious Diseases, 2019, 6, S892-S893.	0.4	0
14	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy–Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. Journal of Infectious Diseases, 2019, 220, 1325-1334.	1.9	18
15	Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2019, 6, ofz086.	0.4	17
16	Sepsis: Personalized Medicine Utilizing â€~Omic' Technologies—A Paradigm Shift?. Healthcare (Switzerland), 2018, 6, 111.	1.0	20
17	Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. Scientific Reports, 2017, 7, 10934.	1.6	36
18	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS ONE, 2015, 10, e0139981.	1.1	45

#	ARTICLE	IF	CITATIONS
19	mi <scp>RNA</scp> s and <scp>HIV</scp> : unforeseen determinants of hostâ€pathogen interaction. Immunological Reviews, 2013, 254, 265-280.	2.8	37
20	Differential Regulation of the Let-7 Family of MicroRNAs in CD4+ T Cells Alters IL-10 Expression. Journal of Immunology, 2012, 188, 6238-6246.	0.4	152
21	The role of microRNAs in HIV-1 pathogenesis and therapy. Aids, 2012, 26, 1325-1334.	1.0	34
22	Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. RNA Biology, 2011, 8, 1035-1046.	1.5	45